Skip to main content
Premium Trial:

Request an Annual Quote

Markers of Depression

Researchers have identified biomarkers that could help diagnose and treat major depression from a blood test, the Economist reports.

Currently, major depression is diagnosed by physicians' assessment of patients' mood, an approach that the Economist notes can be subjective. In the journal Molecular Psychiatry last month, researchers led by Indiana University School of Medicine's Alexander Niculescu analyzed blood samples from an initial cohort of 44 people with a mood disorder to identify genes whose expression changed with differences in patients' symptoms. After testing these RNA expression markers in additional cohorts, the researchers uncovered a panel of 13 biomarkers that can not only detect depression but also predict who might go on to develop bipolar disorder. The Economist notes that three of the genes in the panel may also give insight into which treatment may be the most appropriate.

As GenomeWeb reports, Niculescu is also a co-founder of MindX Science, which is currently offering RNA expression biomarkers testing for psychiatric conditions as laboratory-developed blood tests and following further validation, plans to seek approval from the US Food and Drug Administration for its tests.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more